Ortho-McNeil Ultram
Executive Summary
FDA advisory committee discussion of scheduling status for tramadol is rescheduled for April 28. The Drug Abuse Advisory Committee will also evaluate the effectiveness of the independent steering committee in detecting and preventing Ultram abuse. The meeting will take place at the Gaithersburg, Md. Holiday Inn beginning at 8:30 a.m. The meeting was originally scheduled for Feb. 19 but was postponed to give the advisory committee time to review data ("The Pink Sheet" Feb. 16, In Brief). The committee will meet in closed session April 27...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth